Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma.
Michael L WangWojciech JurczakPier Luigi Luigi ZinzaniToby Andrew EyreChan Yoon Y CheahChaitra S UjjaniYoungil KohKoji IzutsuJames N GersonIan W FlinnBenoît TessoulinAlvaro J AlencarShuo MaDavid John LewisEwa Lech-MarandaJoanna M RhodesKrish PatelKami MaddocksNicole LamannaYucai WangConstantine S TamTahla MunirHirokazu NagaiFrancisco Hernandez-IlizaliturriAnita KumarTimothy S FenskeJohn Francis SeymourAndrew D ZelenetzBinoj NairDonald E TsaiMinna BalbasRichard A WalgrenPaolo AbadaChunxiao WangJunjie ZhaoAnthony R MatoNirav N ShahPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Pirtobrutinib is a first-in-class novel non-covalent (reversible) BTKi, and the first BTKi of any kind to demonstrate durable efficacy following prior cBTKi therapy in heavily pre-treated relapsed/refractory MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation due to toxicity.